Compare WPRT & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WPRT | GRML |
|---|---|---|
| Founded | 1995 | N/A |
| Country | Canada | United States |
| Employees | N/A | 5 |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6M | 41.9M |
| IPO Year | 2006 | 2022 |
| Metric | WPRT | GRML |
|---|---|---|
| Price | $2.01 | $0.48 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | 31.0K | ★ 3.4M |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.54 | $0.27 |
| 52 Week High | $4.14 | $0.48 |
| Indicator | WPRT | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 49.28 | 60.70 |
| Support Level | $1.82 | $0.31 |
| Resistance Level | $2.13 | N/A |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 63.83 | 93.28 |
Westport Fuel Systems Inc is an organization engaged in the engineering, manufacturing, and supply of alternative fuel systems and components for transportation applications. It has three operating segments; the Original Equipment Manufacturers segment-design, manufacture, and sell alternative fuel systems, components and electronics, and related engineering services, to OEMs that serve light-duty, medium-duty, and heavy-duty customers, the Independent Aftermarket segment includes IAM products, conversion kits, and components allow for the conversion of vehicles after being sold to the end-user through a network of dealers and installers, and Corporate includes public company activities, corporate oversight, financing and capital allocation.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.